Physician profile
Lauren E Wright
NPI 1891934410
$9,718.28
in general payments reported to CMS, 2019-2025
38 companies · $471 in 2025
The $471 reported for 2025 was more than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,339 · 2022: $2,629 · 2023: $3,252 · 2024: $1,027 · 2025: $471.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,751.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,750.78 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,559.32 | 2021-2025 | |
| Supernus Pharmaceuticals, INC. | $1,046.10 | 2021-2025 | Qelbree, Qelbree |
| Teva Pharmaceuticals USA, INC. | $703.40 | 2021-2025 | Austedo Xr, Uzedy, Austedo Xr |
| Otsuka America Pharmaceutical, INC. | $677.67 | 2021-2025 | Rexulti, Abilify Mycite, Nuedexta |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $556.20 | 2021-2025 | Caplyta |
| Janssen Pharmaceuticals, INC | $445.17 | 2021-2025 | Spravato |
| Ironshore Pharmaceuticals INC. | $427.18 | 2022-2024 | Jornay Pm |
| Tris Pharma INC | $420.86 | 2021-2024 | Dyanavel Xr |
| Takeda Pharmaceuticals U.S.A., INC. | $393.96 | 2021-2024 | Trintellix |
| Bausch Health US, LLC | $389.76 | 2021-2024 | Aplenzin, Wellbutrin |
| Corium, LLC | $373.65 | 2021-2024 | Azstarys |
| Lundbeck LLC | $368.93 | 2021-2025 | Rexulti |
| Alkermes, INC. | $295.83 | 2021-2024 | Aristada, Lybalvi |
| Axsome Therapeutics, INC. | $280.81 | 2022-2025 | Auvelity, Sunosi |
| Almatica Pharma LLC | $265.35 | 2022-2025 | Loreev Xr, Sertraline Hcl |
Show all 38 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Idorsia Pharmaceuticals US INC | $199.30 | 2023 | Quviviq |
| Neurocrine Biosciences, INC. | $192.12 | 2021-2024 | Ingrezza |
| Merck Sharp & Dohme LLC | $135.19 | 2022-2023 | Belsomra |
| Mdd US Operations, LLC | $110.63 | 2021-2022 | |
| Jazz Pharmaceuticals INC. | $98.15 | 2021-2022 | |
| Noven Therapeutics, LLC | $95.38 | 2021-2023 | Xelstrym, Secuado |
| Vanda Pharmaceuticals INC. | $90.91 | 2021-2025 | Hetlioz, Fanapt |
| Neos Therapeutics, Lp | $87.27 | 2022-2023 | Adzenys Xr-Odt |
| Sunovion Pharmaceuticals INC. | $73.81 | 2021-2022 | |
| Adlon Therapeutics L.P. | $59.39 | 2021 | |
| Collegium Pharmaceutical, INC. | $52.99 | 2025 | Jornay Pm |
| Biohaven Pharmaceuticals, INC. | $48.40 | 2021 | |
| Biohaven Pharmaceutical Holding Company Ltd. | $48.02 | 2022 | |
| Novo Nordisk INC | $47.57 | 2023 | Wegovy |
| Eisai INC. | $42.42 | 2021-2024 | |
| Novartis Pharmaceuticals Corporation | $20.97 | 2021 | |
| Avion Pharmaceuticals | $19.38 | 2023 | Methylphenidate Hydrochloride |
| Livanova USA, INC. | $19.25 | 2023 | Vns Therapy Symmetry Model 8103 Generator |
| Vertical Pharmaceuticals, LLC | $16.20 | 2024 | Relexxii |
| Pfizer INC. | $15.22 | 2023 | |
| Amgen INC. | $14.95 | 2022 | |
| Acadia Pharmaceuticals INC | $13.75 | 2025 | Nuplazid |
| Brainsway USA INC | $12.82 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lauren Wright listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.